

Substitute for form 1449A/PTO				Complete if Known	
<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(use as many sheets as necessary)</p>				Application Number	Continuation of 10/028,547
				10/623431	
				Filing Date	July 18, 2003
				First Named Inventor	Jay D. Kranzler
				Group Art Unit	
Examiner Name					
Sheet	1	of	4	Attorney Docket Number	CYPR 100 CIP CON

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	*0-759-299		Eli Lilly & Co.	02-26-1997		
		FR	*2-752-732		Pierre Fabre Medicament	03-06-1998		
N	WOPET	WO	95/22521		Asahi Kasei Kabushiki Kaisha	08-24-1995		
N	WOPET	WO	97/35574		Pierre Fabre Medicament	10-02-1997		
	WOPET	*WO	97/35584		Eli Lilly & Co.	10-02-1997		
N	WOPET	WO	98/08495		Pierre Fabre Medicament	03-05-1998		

Examine Signature	<i>N. Cook</i>	Date Considered	9/27/06
----------------------	----------------	--------------------	---------

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO:** Assistant Commissioner for Patent, Washington, DC 20231.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 10/028,547
				Filing Date	July 18, 2003
				First Named Inventor	Jay D. Kranzler
				Group Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	CYPR 100 CIP CON

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
N		WO PCT	WO 98/36744		Pierre Fabre Medicament	08-27-1998		
		PCT	*WO 99/59593		ElI Lilly & Co.	11-25-1999		✓
		PCT	*WO 00/32178		Mueller	06-08-2000		✓
N		PCT	WO 01/26623		Laxdale Ltd	04-19-2001		✓
		PCT	*WO 02/053140		Pharmacia & Upjohn Co.	07-11-2002		✓

Examine Signature	<i>N. R. R.</i>	Date Considered	9/27/04
----------------------	-----------------	--------------------	---------

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Continuation of 10/028,547
		Filing Date	July 18, 2003
		First Named Inventor	Jay D. Kranzler
		Group Art Unit	
Examiner Name			
Attorney Docket Number	CYPR 100 CIP CON		

Sheet 3 of 4

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
h		ARDID, et al., "Antidepressants and pain," La Lettre de Pharmacologie 13: 8 (1993).	
h		Cypress Bioscience, Inc., Investor Fact Sheet, August 2001.	
a		DRYSON, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000).	
		*DWIGHT, et al., "An open clinical trial of venlafaxine treatment of fibromyalgia," Psychosomatics 39: 14-17 (1998). ✓	
		GOODNICK, et al., "Psychotropic treatment of chronic fatigue syndrome and related disorders," J. Clin. Psychiatry 13-20 (1993).	
		MEDLINE, et al., "Treatment of chronic fatigue syndrome with sibutramine," PCT Int'l Appl. 14 (09/28/2000).	
u		NAGAOKA, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a case report," Med. Drug. J. 37: 10 (2001).	
		*NINAN, "Use of venlafaxine in other psychiatric disorders," Depression Anxiety 12S: 1:90-94 (2000). ✓	
n		NOGUCHI, et al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity," Synapse 31: 87-96 (1999).	
		*NUTT & JOHNSON, "Potential applications of venlafaxine," Rev. Contemp. Pharmacother. 9: 321-331 (1998). ✓	

Examiner's Signature	<i>Neok</i>	Date Considered	9/22/04
----------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	Continuation of 10/028,547		
		Filing Date	July 18, 2003		
		First Named Inventor	Jay D. Kranzler		
		Group Art Unit			
		Examiner Name ¹			
Sheet	4	of	4	Attorney Docket Number	CYPR 100 CIP CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		*RAO, "The neuropharmacology of centrally-acting analgesic medications in fibromyalgia," Rheum. Dis. Clin. N. Amer. 28: 235-259 (2002).	✓
g		SHUTO, et al., "(±)-Z-2-(Aminomethyl)-1-phenylcyclopropanecarboximide derivatives as a new prototype of NMDA receptor antagonists," J. Med. Chem. 38: 2964-2968 (1995).	
n		SHUTO, et al., "(1S,2R)-1-(phenyl-2-[(s)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy," Jpn. J. Pharmacol. 85: 207-213 (2001).	
u		SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-(phenyl-2-[(s)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist," J. Med. Chem. 39: 4844-4852 (1996).	
n		SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S,2R)-1-phenyl-2-[(r)-1-amino-2-propynyl]-N,N-diethylcyclopropane-carboximide is a novel class of NMDA receptor channel blocker," J. Med. Chem. 41: 3507-3514 (1998).	

Examiner's Signature	<i>Modr</i>	Date Considered	9/27/04
----------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.